

**RESUME & CURRICULUM VITAE**

**WILLIAM F. OWEN, JR., MD, FACP**

## TABLE OF CONTENTS

<b>RESUME.....</b>	<b>3</b>
<b>CONTACT INFORMATION.....</b>	<b>4</b>
<b>EXECUTIVE, ACADEMIC, AND HEALTHCARE LEADERSHIP.....</b>	<b>4</b>
<b>UNIVERSITY ACADEMIC APPOINTMENTS.....</b>	<b>8</b>
<b>VISITING LECTURESHIPS &amp; PROFESSORSHIPS.....</b>	<b>8</b>
<b>COURSES &amp; PROGRAMS OF INSTRUCTION.....</b>	<b>8</b>
<b>RESEARCH TRAINEES.....</b>	<b>8</b>
<b>SELECTED HOSPITAL AND BOARD APPOINTMENTS.....</b>	<b>8</b>
<b>LEADERSHIP IN PROFESSIONAL SOCIETIES AND MEMBERSHIPS.....</b>	<b>11</b>
<b>AWARDS, HONORS, AND RECOGNITION.....</b>	<b>12</b>
<b>INDEX LISTINGS.....</b>	<b>13</b>
<b>EDUCATION AND POSTGRADUATE TRAINING .....</b>	<b>13</b>
<b>MEDICAL CERTIFICATION AND LICENSES .....</b>	<b>13</b>
<b>COMMUNITY &amp; GOODWILL SERVICE.....</b>	<b>13</b>
<b>RESEARCH INTERESTS.....</b>	<b>14</b>
<b>RESEARCH GRANTS &amp; CONTRACTS.....</b>	<b>14</b>
<b>PATENT AWARD.....</b>	<b>15</b>
<b>RESEARCH REVIEWER.....</b>	<b>15</b>
<b>PUBLICATIONS.....</b>	<b>15</b>
<b>JOURNAL ROLES.....</b>	<b>26</b>
<b>ADDITIONAL PERSONAL INFORMATION.....</b>	<b>26</b>
<b>APPENDIX 1.....</b>	<b>27</b>
<b>PROFESSIONAL REFERENCES.....</b>	<b>28</b>

## RESUMÉ



Dr. William F. Owen, Jr., M.D., FACP is a seasoned academic health system (AHS) leader in care, education, research, and community engagement. He was most recently Dean & Chancellor for Ross University of Adtalem Global Education. Ross is the 2<sup>nd</sup> largest allopathic medical school in No. Am. He provided executive oversight for academics, operations, and student experiences with P&L authority for \$250 million budget.

Before Ross, Dr. Owen was:

- CEO, Sidra Medical & Research Center, 2012-14: Cornell's major international AHS partner (Doha, Qatar) with \$1.3 billion budget. He transitioned Sidra from a construction project to opening readiness including international accreditation.
- President, University of Medicine & Dentistry of NJ (now merged with Rutgers), 2007-12: Was the largest freestanding AHS with a \$1.7 billion budget for 8 graduate health schools and 4 research institutes with NJ's largest research budget of \$230 million.
- Chancellor and SVP Health Affairs, University of Tennessee (UTN), 2005-07: With a \$370 million budget, executive oversight of 6 graduate health schools, affiliated research hospitals like St Jude Children's Hospital, and \$125 million research budget.
- Chief Scientist, Renal, Baxter International, 2002-05: A Fortune 200 medical device and drug company with a \$260 million renal research budget.
- Director, Duke University Institute of Renal Outcomes Research, 1999-01: A health policy and clinical trials research Institute with \$1 million budget.
- International Medical Director, National Kidney Foundation Singapore, 1997-04: Nonprofit public funded, national dialysis provider with \$55 million budget as SE Asia's largest dialysis provider.
- Director, Chronic Kidney Disease Program, Harvard's Brigham & Women's Hospital (BWH), 1995-99: Led the renal practice plan for US News' #1 renal program.

A high honor graduate of Tufts Univ. Med. School, and trainee and doctor at BWH for 19 yrs. Dr. Owen was a Professor of Medicine at Duke, UTN, and Am. University of Caribbean; Visiting Scholar of Health Sector Management at Fuqua; and Visiting Professor at Imperial College London's Institute Global Health Innovation. He's authored over 180 articles, chapters, books, and AHRQ-certified clinical practice guidelines. An Overseer at NIH's Warren Magnuson Hospital. Dr. Owen was Sr. Advisor to the President of Int. Assoc. of University Presidents, a UN advisory NGO. He is a past Director of Assoc. of Academic Health Centers, Member of Medicare Coverage Advisory Committee, Americares' Eastern EU Site Inspector, and President of Renal Physicians Assoc. His work is recognized by awards and honors like the National Medical Association's Scroll of Honor, US Congressional Record, Preside Obama's WH Champions of Change, profiled in Ebony Magazine, and Becker's Afro-Am Healthcare Leaders.

## CURRICULUM VITAE

### WILLIAM F. OWEN, JR., MD, FACP

#### Contact:

90 Alton Road, Unit 2306  
Miami Beach, FL 27707

711 Derby Court  
Durham, NC 27707

Mobile (973) 955-7141

E-mail: wfowenmd@aol.com or wfowenmd@icloud.com

---

A strategic academic health system (AHS) executive with a passion for creating social justice through health.

#### EXECUTIVE, ACADEMIC, AND HEALTHCARE LEADERSHIP POSITIONS

##### 1) Adtalem Global Education, Inc. (ATGE)

ATGE (Downers Grove, IL), S&P MidCap 400 Index, is a publicly traded, for-profit higher education provider. Ross University School of Medicine (RUSM) is a principal ATGE asset.

- **Executive Consultant for Medical School Operations, 2020**

Provided strategic counsel to President during my transition

Tasks:

- Counsel on initiatives to sustain increased minority student enrollment

- **Chancellor and Dean, Ross University School of Medicine (RUSM), 2017–19**

RUSM is the 2<sup>nd</sup> largest medical school in No. Am. with ~2,800 students, who are disproportionately from lower economic quintiles. 25% of students are black or Latinx (>2x US average). Basic sciences are in Barbados, and ~900 faculty oversee clinical training at 19 US sites. >50% of 16,000 alumni practice primary care often in low resource locales. I reported to ATGE President and RUSM Board. My most impactful accomplishments were

- ✓ Led changes to raise students' academic performance to their highest, and
- ✓ Increased student diversity to the highest of majority serving medical schools.

Showcase Accomplishments:

- Created Credo and 5-year Strategic Plan to promote student access, academic success, and career attainment
- Initiated digital transformation of teaching and learning pre-pandemic
- α-tested novel articulated admission program for under-represented minorities from Hispanic Serving Institutions and Historically Black Colleges & Universities

- **Dean of Medical Sciences, American University of the Caribbean (AUC), 2016**

AUC is ATGE's smaller med. school, where I oversaw education and operations.

##### 2) Qatar Foundation (QTF) for Education, Science, & Community Development

QTF is a large operating trust led by Her Highness (HH) Sheikha Moza bint Nasser. QTF's aim is to evolve Qatar to a knowledge-based economy.

- **Inaugural CEO, Sidra Medical & Research Center, 2012-14**

Sidra (Qatar) is a 400-bed hospital and research affiliate of Cornell Univ. targeting women and children of Middle East & No. Africa. I reported to HH and the international BOT. My most impactful accomplishments were

- ✓ *Transitioning Sidra from a \$6 billion construction project to opening*
- ✓ *Principal in development of national single payer insurance plan*

Selected Showcase Accomplishments:

- Created Strategic Plan for opening within a \$1.3 billion budget
- Recruited C-suite leadership
- Oversaw development of multi-year operational framework for major services
- Created population-based research strategic plan around gene editing
- Partnered with Hamad Medical Corp. to create an integrated national health delivery system
- Led proof of principle  $\alpha$ -test for transportation interventions under social determinants of health program
- Sidra's global ambassador to health organizations, e.g., Bill & Melinda Gates Foundation and World Innovation Summit of Health (WISH)

3) University of Medicine & Dentistry of New Jersey (UMDNJ)

UMDNJ, now merged with Rutgers, was the largest free standing health university with ~16,000 faculty and staff (NJ's 6<sup>th</sup> largest employer) and 5,600 undergraduate and graduate students. Comprised of 3 nationally ranked medical schools and colleges of allied health, dentistry, graduate research, nursing, and public health, UMDNJ faculty staffed NJ hospitals and Federal certified research Institutes. UMDNJ oversaw NJ's correctional and mental health services. I reported to the BOT. My most lasting accomplishments were

- ✓ *Oversaw turnaround of consequences from Federal Deferred Prosecution Agreement*
- ✓ *Established mobile and neighborhood-based interprofessional health services*

- **3<sup>rd</sup> President, 2007-12**

Some Showcase Accomplishments:

- Revised hospital contracts, affiliation agreements, and faculty practices to Stark II compliance to expedite discharge of Prosecution Agreement
- Met operating income targets under a \$1.7 billion budget. Increased total research expenditures to NJ's highest of \$230 million
- Conveyed 3 research buildings including BCL-3
- Redirected research portfolio for School of Osteopathic Medicine to health services, which raised Federal expenditures to be #1 for osteopathy in US.
- $\alpha$ -tested programs targeting social determinants of health, e.g., "Hot Spots" under Dr. Jeffrey Brenner who was MacArthur Awardee
- Created clinical research organization. Facilitated development of David Alland's rapid DNA field test for tuberculosis -- now the WHO's gold standard
- Increased endowment to \$250 million

4) University of Tennessee (UTN)

TN's flagship academic health system is comprised of nationally ranked colleges of medicine, allied health, dentistry, graduate health, nursing, and pharmacy; and 3<sup>o</sup> care,

rural, and safety net hospital affiliates; and telehealth designed for rural care. ~2,000 students were taught by 4,000 faculty across 4 campuses. Points of pride were

- ✓ With clinical faculty, developed alternate care and costs model for TN Medicaid Waivers program with Sec. Health, Dept. Public Health, and TN. Med. Assoc
- ✓ Created public-private partnership for employment training for indigent women
- ✓ Established SPH with Univ. Memphis for workforce strategy to lower adult and child mortality in blacks

- **10<sup>th</sup> Chancellor and Inaugural Sr. Vice President of Health Affairs, 2005-07**

Showcase Accomplishments:

- Member of the System President's Cabinet with oversight for \$370 million budget and \$125 million research expenditures
- Raised UTN's operating revenue to align with reduced State appropriations
- Oversaw conveyance of 2 basic science research buildings including a BCL 3
- Developed interprofessional model for quality improvement heralded by Institute for Healthcare Improvement
- Was a principal in UTN's successful \$1 billion capital campaign

5) Baxter International

Baxter (Deerfield, IL [Fortune Magazine #185]) develops devices to treat kidney disease

- ✓ *My most noteworthy achievement was the global launch of Extraneal dialysis solution*

- **Chief Scientist, Renal, 2002-05**

Oversaw global research, development, product acquisition, and market surveillance across 8 global sites with a \$260 million budget.

Showcase Accomplishments:

- Oversaw epidemiologic analysis of global outbreak of sterile peritonitis that resulted in a new test for sterility that was added to pharmacopeia
- Successfully advocated for higher CMS payment for home dialysis

6) Duke University School of Medicine/ Duke University Medical Center (DUMC)

DUMC (Durham, NC) is the youngest of the 10 top medical schools and health systems.

- ✓ *My most impactful achievement was prompting my health services research into a national health quality improvement mandate.*

- **Founding Director, Institute of Renal Outcomes Research & Health Policy, 1999-2001**

With an operating budget of ~\$1 MM, conducted investigator-initiated clinical trials, population health studies, and health services research – all purposed for health policy impact.

Showcase Accomplishments:

- Developed health services research program focused on Medicare health disparities
- Led for mandatory national public reporting of dialysis quality for Medicare
- Developed rules for value-based purchasing of dialysis services for Medicare

7) National Kidney Foundation of Singapore (NKF-S)

NKF-S provides national dialysis services, patient support, employment training, and research. With a \$55 million budget, I reported to the Executive Director and BOD.

✓ *My most impactful achievement was improving clinical quality measurements to exceed the US.*

• ***Inaugural Int. Executive Medical Director/ Chair, Intl. Medical Advisory Board, 1997-2004***

Showcase Accomplishments:

- Developed and implemented evidence-based clinical practice guidelines
- Provided a reputational uplift that increased donations 17x, created a \$200 MM endowment, and doubled the number of dialysis centers to 14 (most in SE Asia)

8) Harvard Pilgrim Health Plan (HPHP)

HPHP is a large multi-specialty group practice and a major clinical training site for BWH.

• ***Director, Nephrology Services, 1996-99***

Practice plan leader supervising HPHP nephrologists.

Accomplishment:

- **Implemented and monitored performance measures** for improved care and costs

9) Brigham and Women's Hospital (BWH)/ Harvard Medical School

BWH is Harvard's 2<sup>nd</sup> largest teaching hospital. Site of the 1<sup>st</sup> kidney transplant.

✓ *My most meaningful achievement was to return the BWH Kidney Disease Program to #1 ranking by US News.*

• ***Director, Dialysis & Chronic Kidney Disease Section, 1995-99***

Showcase Accomplishments:

- Developed community-based interprofessional kidney disease education program
- Supervised Harvard faculty nephrologists in shared oversight of trainees
- Oversaw clinical performance measures for treating kidney disease
- Developed the globally used measurement and performance benchmark to measure the quality of dialysis, i.e. Urea Reduction Ratio
- Reported systemic inadequacy of dialysis care for Medicare beneficiaries especially by patients' race, provider profit status, and location. Reported findings in NEJM and testified to several Federal oversight groups, aka "Deadly Dialysis"

10) Fresenius Medical Care (FMC)

FMC provides dialysis services globally.

✓ *One my most significant accomplishments was to establish a first for dialysis unit locales, i.e., placed a flagship dialysis unit in an impoverished urban community.*

• ***Medical Director of The Mary Eliza Mahoney Dialysis Center, Kidney Center, Westwood Dialysis Unit, and Medford Dialysis Center, 1988-99***

Accomplishments:

- Created interprofessional kidney disease care and education programs for patients and their high-risk families in FMC's dialysis centers
- Oversaw quality of care at dialysis centers staffed by both academic and private practice nephrologists
- Managed the remote BWH nephrology practice plans at dialysis units

- Principal interface with State regulators and licensing authorities

#### **UNIVERSITY ACADEMIC APPOINTMENTS**

- Professor of Behavioral & Clinical Medicine, American University of the Caribbean, 2016
- Professor of Medicine with Tenure, University of Tennessee, 2005
- Sr. Scholar, Health Sector Management, Fuqua School of Business, Duke University, 2005
- Professor of Medicine with Tenure, Duke University, 2002
- Associate Professor of Medicine with Tenure, Duke University, 1999
- Assistant Professor of Medicine, Harvard University, 1988
- Instructor in Medicine, Harvard University, 1987

#### **VISITING PROFESSORSHIPS AND LECTURESHIPS (1995-2014)**

Duke University; Hahnemann University; Howard University; Imperial College, London; Louisiana State University; Morehouse School of Medicine; National University of Singapore; Pfizer Visiting Professor, University of California Los Angeles; University of Illinois, Chicago; University of Iowa; University of Utah

#### **MAJOR COURSES AND PROGRAMS OF INSTRUCTION**

These are tabulated in Appendix 1. Five of them were major academic conferences in international venues with >500 attendees.

#### **RESEARCH TRAINEES (1987-2003)**

Most of the research trainees remain in the academy, many now at the level of Professor at nationally ranked institutions.

- Jeffrey Blander, M.S. (USA)
- Joshua Boyce, M.D. (USA)
- Ann Cashion, R.N., Ph.D. (USA)
- Benjamin Chua, M.D., M.R.C.S., M.H.S. (Singapore)
- Joseph Coladonato, M.D., M.H.S. (USA)
- Todd Griffith, M.D., M.H.S. (USA)
- Susan Hedayati, M.D., M.H.S. (USA)
- Ernt Her, Ph.D. (Korea)
- Fan Fan Hou, Ph.D., M.D. (China)
- Preston Klassen, M.D., M.H.S. (USA)
- Eduardo Lacson, M.D., M.P.H. (Philippines)
- Titus Lau, M.D., (Singapore)
- Carolyn Ling, M.D. (USA)
- Francois Madore, M.D., M.P.H. (Canada)
- Lori Orlando, M.D., M.P.H. (USA)
- Max Prempeh, M.D. (USA)
- Deborah Price, M.D. (USA)
- Donal Reddan, M.B., M.R.C.P.I., M.H.S. (Ireland)
- Marc Rothenberg, M.D., Ph.D. (USA)
- Wolfgang Winklemayer, M.D., M.P.H. (Austria)

#### **MAJOR HOSPITAL APPOINTMENTS**

- Duke University Hospital and Duke Associated Physicians, 1999-2001
  - Attending Physician in Nephology and Internal Medicine



- Roxboro Dialysis Unit
- Brigham & Women's Hospital, 1990-99
  - Attending Physician in Nephology and Internal Medicine
  - Director, Chronic Kidney Disease section
  - Medical Director of affiliated dialysis units

## **SELECTED BOARD APPOINTMENTS**

### **Governance, Advocacy, and Oversight**

- Co-Chair, Platform Committee, St. Maarten Ministry of Public Health, Social Development and Labor, 2016-17
  - St. Maarten government policy development and public health oversight body
- Chair, Board of Directors, Be Jersey Strong, 2015-17
  - Community-based program using undergraduate students as health navigators for enrollment in the Affordable Care Act
  - Initiative was highlighted on NPR and recognized with Champion of Change White House Award by President Obama
- Member, Board of National Health Insurance Co, Qatar Supreme Council of Health, 2013-14
  - Created by Health Ministry to develop a national single payer model for healthcare
- Member, Advisory Board, College of Arts and Sciences, Qatar University, Doha, 2013-14
  - Offered counsel on academic programs for national health workforce planning
- Member, Joint Advisory Board, Weill-Cornell Medical College (NY) and Weill-Cornell Medical College in Qatar, 2012-14
  - An integrated governing body for Cornell and Sidra comprised up of Cornell Deans, Sidra CEO, and Trustees from both institutions
- Member, New Jersey Chamber of Commerce, 2010-12
  - Business development and advocacy body for NJ
  - Content expert on med. ed. institutions and biomedical research as catalyst for economic development and social revitalization
- Site Visit Team Leader, Middle States Commission of Higher Education (MSCHE), 2010-12
  - Oversaw multiple site visit teams for university accreditation under regional contract with US Dept. of Education
  - Presented findings and accreditation recommendation to MSCHE
- Chair, Board of Directors, Eastern Division of CEO's Against Cancer, 2009-11
  - Alliance CEOs of large employers advocating for workplace wellness programs and sharing best practices
- Member, New Jersey Hospital Association, 2009-12
  - Provided content expertise on workforce solutions for hospital staffing and how they may be met through UMDNJ professional schools and career ready training
- Chair, Academic Affairs Committee, Board of Overseers, Tufts U. School of Medicine (TUSM), 2007-12
  - Advisory Board to Tufts President, TUSM Dean, and Board of Trustees on academic performance, curriculum, and student access to TUSM
- Executive Committee, New Jersey President's Council, 2007-12
  - Advisory and authorizing body for all NJ college and university Presidents of public institutions of higher education on academic and student service matters

- Authorizing body for opening and substantive change for institutions and their instructional programs
- Audit Committee, Board of Directors, Kessler Foundation, 2007-13
  - Kessler is one of the US' largest public charities supporting people with acquired disabilities, e.g. traumatic brain injury and stroke
  - Committee charged with oversight of financial reporting to the Board
- Executive Committee, Robert Wood Johnson Health System (RWJHS), 2007-2012
  - Governing body for RWJHS, a multiple hospital system operationally comprised of a nationally ranked tertiary care hospital and ~6 community hospitals with common purchasing, sharing of best practices, and facilitated patient referrals
- Executive Committee, Robert Wood Johnson Hospital (RWJH), 2007-12
  - Governing body for RWJH, which is a 965-bed tertiary care hospital, flagship of the RWJHS, and major UMDNJ teaching and research affiliate
- Executive Committee, New Jersey Council of Teaching Hospitals, 2007-12
  - Advocacy network for NJ's teaching hospitals
- Executive Committee, Council for Higher Education in Newark, 2007-12
  - Governing body for the consortium of 4 institutions of higher education in Newark leveraging their assets for local economic development
  - Established a STEM focused high school in Newark
- Executive Committee, Foundation of UMDNJ, 2007-12
  - Governing body for the 501(c)(3) organization funding UMDNJ's startup research initiatives
- Executive Committee, Board of Directors, Methodist Le Bonheur Health System, 2005-07
  - Governing body for Memphis based, nationally ranked hospital system with 2 tertiary care hospitals and 4 smaller community-based hospitals
- Executive Committee, Board of Directors, University Health System, 2005-07
  - Governing body for Chattanooga's principal tertiary care hospital with two smaller regional hospitals, all staffed by UTHSC clinical faculty
- Executive Committee, University of Tennessee Medical Group, 2005-07
  - Governing body for West Tennessee's multispecialty faculty practice comprised of UTHSC faculty
- Ex officio member, Board of Directors, Regional Medical Center, 2005-2007
  - Governing body for the safety net provider for West TN, No. MS, and W. AK.
  - Staffed by UTHSC faculty
- Executive Committee, Memphis Bioworks Foundation, 2005-07
  - Advisory body for the business incubator for startup life sciences companies affiliated with UTHSC
  - Created and managed a STEM Charter School in Memphis for low resource K-12 students
- Member, Board of Directors, Church Health System, 2005-07
  - Governing body for local faith-based organization providing comprehensive healthcare to under-insured residents
- Member, Medicare Evidence Development and Coverage Advisory Committee (MedCAC), Centers for Medicare & Medicaid Services, 2003-05
  - Advisory expert panel that provides evidentiary facts to CMS for decisions on Medicare coverage of procedures and devices
- Member, Board for Comprehensive Center for Health Disparities, David Geffen School of Medicine, UCLA, and Charles Drew University of Medicine and Science, 2003-05

- Member, Board of Directors, Spencer Spinal Cord Injury Foundation, 2002-04
- Chair, Health Resources & Services Administration and Renal Physicians Association Collaborative, U.S. Department of Health and Human Services, 2001
- Member, U.S. Renal Data System, Centers for Medicare & Medicaid Services, 2000-01
  - National advisory panel for congressionally mandated data collection and public reporting of practice patterns and outcomes for Medicare dialysis patients
- Member, End-Stage Renal Disease Network of Southeastern US, Centers for Medicare & Medicaid Services, 2000-01
- Chair, Vascular Access Committee, National End Stage Renal Disease Quality Improvement Project, Centers for Medicare & Medicaid Services, 2000-05
  - Advisory committee to CMS for data collection and reporting to reduce use of artificial grafts for dialysis patients
- Member, National Kidney Disease Education Program, Council of American Kidney Societies, 1999-00
  - Advisory panel to NIH leading educational initiatives to reduce mortality and morbidity of kidney disease patients
- Member, Board of Overseers, Warren Magnuson Hospital and Clinical Center, National Institutes of Health, 1998-01
  - NIH's hospital and clinics dedicated to clinical research by NIH scientists
  - The Board was an advisory panel comprised of clinical and translational academicians tasked to assess research productivity and to make NIH tenure recommendations
- Member, National End Stage Renal Disease Core Indicator's Advisory Committee, Health Care Financing Administration, 1997-99
  - Made recommendations to CMS on key performance indicators and national performance standards
  - Provided content expertise for assessments and corrective and preventive actions for dialysis programs that were out of compliance
- Chair, End-Stage Renal Disease Network 1, Health Care Financing Admin., 1997-99
  - Oversight body for clinical performance in New England
- Medical Advisory Board, African American Early Renal Disease Intervention Program, American Kidney Fund, 1997-98
- Member, Medical Advisory Board, American Assoc of Kidney Patients, 1996-2005
  - National advocacy association for kidney disease patients

#### **LEADERSHIP ROLES IN PROFESSIONAL SOCIETIES**

- Member, Board of Directors, Association of Academic Health Centers International, 2012-14
  - Subsidiary member organization to Assoc. of Academic Health Centers (AAHC) that advances global health through adoption of American educational and business models
- Member, Board of Directors, Association of Academic Health Centers, 2010-12
  - Governing body for 501(c)(3) member organization that advances health by adoption of best management practices across all health professions at AHS
  - Advocates for national health workforce planning through
- Sr. Health Policy Advisor to President J. Michael Adams, International Association of University Presidents (IAUP), 2010-12
  - Global association of university chief executives with highest UN consultative rights

- Newly created position to advise President Adams on the role of higher education in response to pandemics
- Advisor to the membership on approaches to increase diaspora healthcare workers
- Member, Board of Directors, Medical Society of New Jersey, 2010-12
- President, Renal Physicians Association's Education Foundation, 2003-05
- President, Renal Physicians Association (RPA), 2001-03
  - RPA is the national member society advocating for practicing nephrologists
  - Principal liaison to CMS, MCAC, MEDPAC (Medicare Payment Advisory Commission), RUC (RVS Update Committee), and state licensing bodies on practice issues for nephrologists
  - Provided Congressional testimony on several occasions

#### **OTHER CURRENT AND PAST PROFESSIONAL SOCIETY MEMBERSHIPS**

American Council on Education, American College of Physicians, American Medical Association, Dade County Medical Society, Federation of American Societies for Experimental Biology, North Carolina Medical Society, Hispanic Association of Colleges and Universities, Massachusetts Medical Society, National Medical Association, New Jersey Medical Society, NC Medical Society, Renal Physicians Association, Tennessee Medical Association

#### **SELECTED AWARDS, HONORS, AND SPECIAL RECOGNITION**

- Becker's Hospital Review, 68 African American Leaders in Healthcare, 2019, 2020
- Resolution of Recognition, Senate and General Assembly, State of New Jersey, 2017
- The White House Champions of Change Award, 2016
- Congressional Tribute by Congressman Donald Payne, US House of Representatives, 112<sup>th</sup> Congress, 2012
- University Resolution of Appreciation, UMDNJ Board of Trustees, 2012
- Resolution of Recognition, Senate and General Assembly, State of New Jersey, 2012
- Outstanding Medical Executive, Edward J. Ill Excellence in Medicine Awards, 2012
- National Distinguished Alumnus, National Medical Fellowships, 2011
- Pioneer Award, Student National Medical Association, 2010
- Scroll of Merit (highest honor), National Medical Association, 2009
- Distinguished Service Medal, Department of Military & Veterans Affairs, New Jersey, 2009
- Academy of Leaders, NJ Martin Luther King Commission, 2009
- Certificate of Appreciation, NJ Latino Heritage Committee, 2009
- Honorary Associate Chair, NJ State Committee for Israel @ 60, 2009
- Proclamation of Investiture and Dedication, Gov. Jon Corzine, State of New Jersey, 2007
- Fellow, American College of Physicians, 2007
- Administrator of the Year, Faculty Senate, University of TN, 2006
- 25<sup>th</sup> Year Distinguished Alumnus, Tufts University School of Medicine, 2005
- Certificate of Recognition, Mayor Willie Herenton, Memphis, TN, 2005
- Office Director's Citation, Health Care Financing Administration, 2000
- Community Service Award; Roxbury, Dorchester, Mattapan, and Hyde Park Patient Group, 1998
- National Recognition Award, Amgen Corporation, 1997
- National Distinguished Service Award, National Kidney Foundation, 1996, 1997
- Merit & Achievement Certificate, Senate of Massachusetts, 1996

- National Medical Fellowship, Henry J. Kaiser Foundation, 1980
- Alpha Omega Alpha Medical Honor Society, 1979

#### **INDEX LISTINGS (1997-2015)**

- Best Doctors in America, Best Doctors in Boston, Best Doctors in Chicago, Who's Who in America, Who's Who in Medicine & Healthcare, Who's Who in American Education, Who's Who in the South and Southwest, Who's Who in the East, 50 Most Powerful People in Healthcare in New Jersey, 50 Most Influential Blacks in New Jersey, Power Players

#### **EDUCATION**

- Tufts University School of Medicine, MD with high honors, (Boston, MA), 1976-80
- Brown University, BA, (Providence, RI), 1973-76
- Phillips Academy ([aka Andover], Andover, MA), 1969-73

#### **POSTGRADUATE TRAINING**

- Seminar for Experienced University Presidents, Harvard Graduate School of Education, Inaugural class of 2010
- Minority Medical Faculty Development Program, Robert Wood Johnson Foundation, 3<sup>rd</sup> class. Mentored by Harvard's Dean Dr. Harold Amos, 1985-89
- Postdoctoral Research Fellow, Department of Rheumatology and Immunology, Harvard Medical School, Supervised by Professor K. Frank Austen, 1984-87
- Clinical Fellow in Nephrology and Transplantation, Brigham and Women's Hospital, Harvard Medical School, 1983-85
- Resident Physician in Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, 1980-83

#### **MEDICAL CERTIFICATIONS**

Granted lifetime certification by ABIM

- American Board of Internal Medicine, 1983-present
- American Board of Internal Medicine, Nephrology, 1985-present

#### **MEDICAL LICENSES**

- Tennessee, Medicine, 2006-2011 (voluntary retirement)
- North Carolina, Medicine, 1999-present (active)
- Massachusetts, Medicine, 1980-2007 (voluntary retirement)

#### **COMMUNITY AND GOODWILL SERVICE**

- The Brotherhood, 2010-present
- Newark Preschool Council Reading Club, 2011-12
- Middle States Commission of Higher Education, Site Visit Chair, 2010-12
- Chairman, Higher Education Division, United Way, 2006-07
- Sigma Pi Phi Fraternity, Delta Boule Chapter (Memphis, TN), 2006-present
- Advisory Group for Shelby County Mayor AC Wharton, 2005-07
- Advisory Group for Memphis City Mayor Willie Herrington, 2005-07
- Chicago Museum of Science and Industry, Life and Health Task Force, 2003-04
- Hillandale Elementary School, Site-Based Committee, 2000-01
- Roxbury, Dorchester, Mattapan, Hyde Park Patient Support Group, 1997-99
- AmeriCares, Site Reviewer, Eastern Europe, 1995-96

- Boston Chapter of Friends of the Elderly, 1992-99
- Co-founder, Ruth Margaret Easterling [Scholarship] Fund, Tufts University School of Medicine, 1979-present

### RESEARCH INTEREST

My research portfolio was principally funded by five competitive R0-1 and two U0-1 grants. My research portfolio focused on: (1) racial and ethnic disparities in health utilization and outcomes for Medicare beneficiaries, (2) impact of national quality improvement initiatives and reimbursement models on physicians' practice patterns under Medicare, (3) predictors of survival for patients with chronic kidney disease, and (4) cytokine regulation of eosinophil function in the effector limb of adaptive immunity.

### RESEARCH GRANTS AND CONTRACTS

#### Federally Funded Research Grants

YEAR	GRANT #	TITLE	AMOUNT	SOURCE
1989-94	P01 HL 36110-07	Chemical Mediators of Acute Pulmonary Disorders	\$704,058	NIH/NHLBI
1990-93	R37 AI 22531-08	Chemical Mediators of Acute Pulmonary Disorders	\$134,484	NIH/NHLBI
1991-95	U01 AI 31599-01	Cellular Basis of Hypersensitivity Diseases in Humans	\$336,061	NIH/NIAID
1992-98	R01 DK45656-01	Monocyte Phenotypes and Morbidity in Uremia	\$595,204	NIH/NIDDK
1994-99	U01 DK49259-01	Mortality & Morbidity in Hemodialysis Study	\$1,133,390	NIH/NIDDK
1996-98	R01 HS09398-02	Nephrologist Care & Outcomes Renal Insufficiency	\$639,975	AHCPR/HCFA in
2001-03	R0-1	Effect of Renal Insufficiency Cardiovascular Outcomes	\$450,000	NIH/NIDDK
2001-09	R01 HS013345-01	Hypertension Improvement Project	\$2,191,761	NHLBI
2001-05	R01 HS013345-01	Dialysis Facility Management	\$350,000	HCFA/AHCPR

#### Non-Federally Funded Research Grants

YEAR	TITLE	AMOUNT	SOURCE
1985-89	Subcellular Localization of LTC <sub>4</sub> Synthetase	\$260,000	Robert W. Johnson Foundation
1993-96	Efficacy of Topical Cromolyn for Uremic Pruritis	\$67,634	Ascent
1993-96	Estrogen Replacement Therapy for Cardiovascular Risk in ESRD	\$106,893	Baxter Int.

2000-01	Crit-line Intradialytic Monitoring Benefit Study	\$637,000	In-Line Diagnostics
2000-01	Non-conventional Cardiac Risk Factors Associated with Kidney Disease	\$60,000	Amgen, Inc
2000-02	Developing Clinical Practice Guidelines for Management of Pre-ESRD Patients	\$400,000	Renal Physicians Assoc.
2001-05	Correcting Hemoglobin & Outcomes in Renal	\$2,138,599	Ortho Biotech

#### **FEDERAL PATENT**

Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions, #77118857, Issued 10/10/06

#### **REVIEWER FOR FEDERAL SPONSORED RESEARCH**

##### **U.S. Department of Health and Human Services**

###### **National Institutes of Health**

- Clinical Sciences, 1999
- National Analgesic Nephropathy Study, Chairman, National Institute of Diabetes, Digestive, and Kidney Diseases, 1998-99
- Task Force on Daily Dialysis, Co-Chairman, National Institute of Diabetes, Digestive and Kidney Diseases, 2001
- Daily In-center Dialysis Trial, Chairman, National Institute of Diabetes, Digestive and Kidney Diseases, 2001
- Chronic Renal Insufficiency Cohort Study, National Institute of Diabetes, Digestive and Kidney Diseases, 2001
- Clinical Trials Unit, Chairman, Charles R. Drew University, National Institute of Diabetes, Digestive and Kidney Diseases, 2003
- African-American Study of Kidney Disease Cohort Study, Chairman, National Institute of Diabetes, Digestive and Kidney Diseases, 2003
- Boston Area Community Health Epidemiologic Survey of Urological Conditions-Coverage of Interstitial Cystitis and Chronic Pelvic Pain, Chairman, National Institute of Diabetes, Digestive and Kidney Diseases, 2003
- FAVORIT Trial, Chairman, National Institute of Diabetes, Digestive, and Kidney Diseases, 2006

###### **Health Care Financing Administration** (now Centers for Medicare & Medicaid Services)

- Costs of Dialysis and Cost-Effectiveness of HEMODialysis Study, 1997

#### **PUBLICATIONS**

##### **Peer-Reviewed, Original Publications**

1. Silberstein DS, Owen WF, Gasson JC, DiPersio JF, Golde DW, Bina JC, Soberman RJ, Austen KF, David JR: Enhancement of human eosinophil cytotoxicity and leukotriene biosynthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. *J Immunol.* 1986;137:3290-4.
2. Owen WF, Soberman RJ, Yoshimoto T, Sheffer A, Lewis RA, Austen KF: Synthesis and release of leukotriene C4 by human eosinophils. *J Immunol.* 1987;138:532-8.
3. Owen WF, Rothenberg ME, Silberstein DS, Gasson JC, Stevens RL, Austen KF, Soberman RJ: Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. *J Exp. Med.* 1987;166:129-41.

4. Rothenberg ME, Owen WF, Silberstein DS, Soberman RJ, Austen KF, Stevens RL: Eosinophils cultured with endothelial cells have increased survival and functional properties. *Science*. 1987;237:645-7.
5. Rothenberg ME, Owen WF, Silberstein DS, Soberman RJ, Austen KF, Stevens RL: Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3. *J Clin Invest*. 1988;81:1986-92.
6. Rothenberg ME, Pomerantz JL, Owen WF, Avraham S, Austen KF, Stevens RL: Characterization of human eosinophil proteoglycans and regulation of their biosynthesis by interleukin-3, interleukin-5, and granulocyte/macrophage colony-stimulating factor. *J Biol Chem*. 1988;263:13901-8.
7. Owen WF, Rothenberg ME, Petersen J, Weller P, Silberstein DS, Sheffer AL, Stevens RL, Soberman RJ, Austen KF: Interleukin-5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. *J Exp Med*. 1989;170:343-8.
8. Lam B, Owen WF, Austen KF, Soberman RJ: The identification of a distinct export step following the biosynthesis of leukotriene C<sub>4</sub> by human eosinophils. *J Biol Chem*. 1989;264:12885-9.
9. Rothenberg ME, Stevens RL, Silberstein DS, McKenzie DT, Austen KF, Owen WF: Interleukin 5-dependent conversion of normodense eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. *J Immunol*. 1989;143:2311-6.
10. Ling CJ, Owen WF, Austen KF: Human fibroblasts maintain the viability and augment the functional response of human neutrophils in culture. *J Clin Invest*. 1990;85:601-4.
11. Caufield JP, Hein A, Rothenberg ME, Owen WF, Soberman RJ, Stevens RL, Austen KF: A morphometric study of normodense and hypodense eosinophils that are derived in vivo and in vitro. *Am J Pathol*. 1990;137:27-41.
12. Owen WF, Petersen JP, Sheff DM, Folkerth RD, Anderson RJ, Corson JM, Sheffer AL, Austen KF: Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. *Proc Natl Acad Sci (USA)*. 1990;87:8647-51.
13. Her E, Frazer J, Austen KF, Owen WF: Eosinophil hematopoietins antagonize the programmed cell death of human eosinophils: cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell conditioned medium. *J Clin Invest*. 1991;88:1982-7.
14. Owen WF, Petersen J, Austen KF: Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. *J Exp Med*. 1991;166:129-41.
15. Kay J, Benson CB, Lester S, Corson JM, Lazarus JM, Owen WF. Utility of high resolution ultrasound for the diagnosis of dialysis-related amyloidosis. *Arthritis Rheum*. 1992;35:926-32.
16. Owen WF, Lew NL, Lui Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as mortality predictors for maintenance hemodialysis patients. *N Engl J Med*. 1993;329:1001-5.
17. Lazarus JM, Owen WF: Effect of biocompatibility on morbidity and mortality. *Am J Kidney Dis*. 1994;24:1019-23.
18. Boyce J, Friend D, Matsumoto R, Austen KF, Owen WF: Differentiation in vitro of hybrid eosinophil/basophil granulocytes - autocrine function of an eosinophil developmental intermediate. *J Ex Med*. 1995;182:49-57.
19. Boyce J, Friend D, Gurish M, Austen KF, Owen WF. Constitutive production of GM-CSF by mononuclear eosinophils developed in vitro from hybrid eosinophil/basophil granulocytes. *Proc Nat Acad Sci, USA*, 1996;93:2436-41.



20. Chertow G, Owen WF, Lazarus JM. Cost-effectiveness of cancer screening in hemodialysis patients. *Arch Int Med*. 1996;156:1345-50.
21. Ginsburg E, Owen WF, Greenberg LM, Shea BF, Lazarus JM, Walsh B. Estrogen absorption and metabolism in postmenopausal women with end stage renal disease. *J Clin Endo Metab*. 1996;81:4414-7.
22. Boyce J, Friend D, Gurish M, Austen KF, Owen WF. Expression of LTC<sub>4</sub> synthase during the development of eosinophils in vitro from cord blood progenitors. *Blood*. 1996;88:4338-47.
23. Owen WF, Madore F, Brenner B. An observational study of cardiovascular characteristics of long-term ESRD survivors. *Am J Kidney Dis*. 1996;28:931-6.
24. Owen WF: Racial differences in the incidence, outcome, and quality of life for African-Americans on hemodialysis. *Blood Purif*. 1996;14:278-85.
25. Hemodialysis Adequacy Work Group: NKF-DOQI clinical practice guidelines for hemodialysis. *Am J Kidney Dis* 1997;30(Suppl 2) S15-66.
26. Hou F-F, Chertow G, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF. Interaction between  $\beta$ 2-microglobulin and advanced glycation end products in the development of dialysis-related amyloidosis. *Kidney Int* 1997;51:1514-9.
27. DA Price, Owen WF: African-Americans on maintenance dialysis. *Adv Renal Replacement Ther* 1997;4:3-12.
28. Owen WF, Meyer K, Schmitt G, Alfred H, and ESRD Network N Engl. Methodological limitations of the ESRD Core Indicators Project: an ESRD Network's experience with implementing an ESRD quality survey. *Am J Kidney Dis*. 1997;30:349-55.
29. HEMO Study Group. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. *Kidney Int* 1997;51:2013-7.
30. Madore F, Bridges K, Lew N, Lowrie E, Lazarus JM, Owen WF. Anemia in hemodialysis patients: variables impacting this outcome predictor. *J Am Soc Nephrol*. 1997;8:1921-9.
31. HEMO Study Group: Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. *Kidney Int* 1997;52:1395-1405.
32. Hou F-F, Boyce J, Chertow G, Lazarus JM, Owen WF. Aminoguanidine inhibits the formation of advanced glycation end products of  $\beta$ 2-microglobulin. *J Am Soc Nephrol*. 1998;9:277-83.
33. Owen WF, Hou F-F, Stuart RO, Kay J, Boyce J, Chertow G, Schmidt AM:  $\beta$ 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. *Kidney Int*. 1998;53:1365-73.
34. Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Turner JR. Development of gastrointestinal  $\beta$ 2-microglobulin amyloidosis correlates with time on dialysis. *Am J Surg Pathol*. 1998;22:729-35.
35. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. *Kidney Int* 1998; 54:627-36.
36. Owen WF, Chertow G, Lazarus JM, Lowrie EG. The dose of hemodialysis: mortality responses by race and gender. *J Am Med Assoc*. 1998; 280:1764-8.
37. Ginsburg ES, Walsh B, Greenberg L, Price D, Chertow GM, Owen WF. Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. *Kidney Int*. 1998.
38. Frankenfield D, McClellan WM, Helgerson S, Lowrie EG, Rocco M, Owen WF: Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core Indicators Project. *Am J Kidney Dis* 1999;33:584-91.
39. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK, Hemo Study Group: Effects of hemodialyzer reuse on clearances of urea and  $\beta$ 2-microglobulin. *J Am Soc Nephrol* 1999;10:117-27.

40. Depner TA, Greene T, Gotch FA, Daugirdas JT, Keshaviah PR, Star RA, HEMO Study Group: Imprecision of the hemodialysis dose when measured directly from urea removal. *Kidney Int* 1999;55:635-47.
41. Uribarri J, Levin NW, Delmez J, Depner TA, Ornt D, Owen WF, Yan G. Association of acidosis and nutritional parameters in hemodialysis patients. *Am J Kidney Dis* 1999;34:493-9.
42. HEMO Study Group. The Hemodialysis Pilot Study: Nutrition program and participant characteristics at baseline. *J Renal Nutr* In press.
43. Wish J, Roberts J, Beserab A, Owen WF: Cost-effectiveness of the DOQI clinical practice guidelines. *Adv Renal Replacement Ther* 1999;6:67-74.
44. Lowrie EG, Chertow G, Lazarus JM Owen WF: The urea [clearance × dialysis time] product (Kt) as an outcome based measure of hemodialysis dose. *Kidney Int* 1999;56:729-37.
45. Chertow GM, Owen WF, Lazarus JM, Lew SM, Lowrie EG: Exploring the reverse J-shaped curve between URR and mortality. *Kidney Int* 1999; 56:1872-8.
46. Frankenfield DL, Rocco V, Frederick PR, Pugh J, McClellan WM, Owen WF, for the National ESRD Core Indicators Workgroup. Racial/Ethnic analysis of selected intermediate outcomes for in-center hemodialysis patients: results from the 1997 ESRD Core Indicators Project. *Am J Kidney Dis.* 1999; 34:721-30.
47. Frankenfield DL, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF for the ESRD Core Indicators Workgroup. Anemia management of adult hemodialysis patients in the US: patterns of erythropoietin and iron administration. Results from the 1997 ESRD Core Indicators Project. *Kidney Int* 2000; 57:578-89.
48. Hsu S, Ramirez SB, Winn MP, Bonaventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. *Kidney Int* 2000;57:1818-35.
49. Rocco MV, Frankenfield DL, Frederick PR, Pugh J, McClellan WM, Owen WF, for the National ESRD Core Indicators Workgroup. Racial/ethnic analysis of selected intermediate outcomes for peritoneal dialysis ESRD patients: results from the 1997 ESRD Core Indicators Project. *Perit Dial Int* 2000;20:328-35.
50. Steinberg EP, Eknoyan G, Levin N, Eschbach J, Golper TA, Owen WF, Schwab S. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes & Quality Initiative Practice Guidelines: description, findings and implications. *Am J Kidney Dis* 2000;36:1-11.
51. Lau T, Owen WF, Benfell K, Yu YM, Noviski N, Lyons J, Zurakowski D, Tsay R, Ajami A, Young VR, Castillo L. Arginine, citrulline, and nitric oxide metabolism in end stage renal disease patients. *J Clin Invest* 2000;105:1217-1225.
52. Hou FF, Boyce J, Zhang Y, Owen WF. Phenotypic and functional characteristics of macrophage-like cells differentiated in pro-inflammatory cytokine-containing cultures. *Immunol Cell Biol* 2000;78:205-213
53. Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM, Owen WF.  $\beta$ 2-microglobulin modified with advanced glycation end products delays monocyte apoptosis and induces differentiation into macrophage-like cells. *Kidney Int* 2001;59:990-1002.
54. Szczech LA, Lowrie EG, Zhensheng L, Lew NL, Lazarus JM, Owen WF. Changing hemodialysis thresholds for optimal survival. *Kidney Int* 2001;59:738-45.
55. Hemodialysis Adequacy Work Group. NKF/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. *Am J Kidney Dis* 2001;37:S9-64.
56. Nissenson AR, Collins AJ; Dickmeyer J, Litchfield T, Mattern W, McMahonill CN, Muhlbaier L, Nielsen J, Owen WF, Pereira BJG, Steinman TI, Szczech L. Disease state management may improve clinical outcomes of dialysis patients. *Am J Kidney Dis* 2001;37:938-44.
57. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, Hannan EL. Differential

- survival following coronary revascularization procedures among patients with renal insufficiency. *Kidney Int* 2001;60:292-299.
58. Reddan DN, Marcus RJ, Owen WF, Szczech LA, Landwehr DM. Long term outcomes of revascularization for peripheral vascular disease in end stage renal disease patients. *Am J Kidney Dis* 2001;38:57-63.
  59. Winkelmayr WC, Glynn RJ, Levin R, Owen WF, Avorn J. Late referral and modality choice in end-stage renal disease. *Kidney Int* 2001;60:1547-1554.
  60. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 End Stage Renal Disease Core Indicator Project. *Am J Kidney Dis* 2001;37:36E
  61. Winkelmayr WC, Glynn RJ, Levin R, Owen WF, Avorn J. Determinants of delayed nephrologist referral in patients with chronic kidney disease. *Am J Kidney Dis* 2001; 38:1178-1184.
  62. Lowrie E, Teng M, Lacson E, Nancy L, Lazarus JM, Owen WF. The association between prevalent care process measures and facility specific mortality rates. *Kidney Int* 2001; 60:1917-1929.
  63. Ameer GA, Grovender EA, Ploegh H, Ting D, Owen WF, Rupnick M, Langer R. A novel immunoadsorption device for removing  $\beta$ 2-microglobulin from whole blood. *Kidney Int* 2001; 59:1544-1550.
  64. Lacson EK, Teng M, Lazarus JM, Lew N, Lowrie EG, Owen WF. Limitations of the facility-specific standardized mortality ratio for profiling healthcare quality in dialysis. *Am J Kidney Dis* 2001; 37:267-75.
  65. Klassen P, Lowrie EG, Reddan DN, Szczech LA, Lazarus JM, Owen WF. Elevated pulse pressure predicts mortality in maintenance hemodialysis patients. *J Am Med Assoc.* 2002;287:1548-1555.
  66. Coladonato JA, Frankenfield DL, Reddan D, Klassen P, Szczech L, Johnson CA, Owen WF. Trends in anemia management among U.S. hemodialysis patients. *J Am Soc Nephrol* 2002;13:1288-95.
  67. Hynes DM, Stroupe KT, Greer JW, Reda D, Frankenfield DL, Kaufman JS, Henderson WG, Owen WF, Rocco MV, Wish JB, Kang J, Feussner JR. Estimating potential cost savings for erythropoietin administration for end stage renal disease. *Am J Med.* 2002;112:171-175.
  68. Avorn J, Winkelmayr W, Bohn RL, Levin R, Glynn RJ, Levy E, Owen WF. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. *J Clin Epidemiol.* 2002;55:711-716.
  69. Avorn J, Bohn RL, Levy E, Levin R, Owen WF, Winkelmayr WC, Glynn R. Nephrologist care and mortality in patients with chronic renal insufficiency. *Arch Int Med.* 2002; 162:2002-2006.
  70. Reddan D, Klassen P, Frankenfield DL., Szczech L, Schwab S, Coladonato J, Rocco M, Owen WF. National profile of practices patterns for hemodialysis vascular access in the United States. *J Am Soc Nephrol.* 2002;13:2117-2124. .
  71. Eggers PW, Frankenfield DL, Greer JW, McClellan W, Owen WF, Rocco MV. Comparison of mortality and intermediate outcomes between medicare dialysis patients enrolled in HMO and fee for service. *Am J Kidney Dis.* 2002;39:796-804.
  72. Winkelmayr WC, Owen W, Glynn RJ, Levin R, Avorn J: Preventive health care measures before and after start of renal replacement therapy. *J Gen Int Med* 17:588-95, 2002.
  73. Hou FF, Jiang JP, Guo JQ, Wang GB, Zhang X, Stern DM, Schmidt AM, Owen WF. The receptor for advanced glycation end products on human synovial fibroblasts: Role in the pathogenesis of dialysis-related amyloidosis. *J Am Soc Nephrol.* 13:1296-1306, 2002.

74. McCrory D, Klassen P, Rutschmann O, Coladonato J, Yancy W, Reddan D, Gray R, Owen W, Shurr E, Matchar D. Evidence Report: Appropriate Patient Preparation for Renal Replacement Therapy. October 2002. Renal Physicians Association. Rockville, MD.
75. Winkelmayr WC, Owen WF, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. *J Am Soc Nephrol* 2003; 14:486-92.
76. Reddan DN., O'Shea JC, Sarembock IJ., Williams KA., Karen S. Pieper, Edward Santoian, William F. Owen, Jr, Michael M. Kitt, James E. Tchong, Treatment effect of eptifibatide in planned coronary stent implantation may be enhanced in patients with chronic kidney disease - results from the ESPRIT trial. *Am J Cardiol* 2003; 91:17-21.
77. Reddan DN, Frankenfield DL, Klassen PS, Coladonato JA, Szczech L, Johnson CA, Besarab A, Rocco M, McClellan W, Besarab A, Wish J, Owen WF. Regional variability in anemia management and hemoglobin in the U.S. *Nephrol Dial Transpl* 2003; 18:147-52.
78. Lowrie EG, Teng M, Lew NL, Lacson EJ, Lazarus JM, Owen WF. Towards a continuous quality improvement paradigm for hemodialysis providers with preliminary suggestions for clinical practice monitoring and measurement. *Hemodialysis Int* 2003; 7:28-51.
79. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF, Lowrie EG. White blood cells as a novel mortality predictor in hemodialysis patients. *Nephrol Dialysis Transpl* 2003;18:1167-73.
80. Tonelli M, Winkelmayr W, Jindal KK, Owen WF, Manns BJ. The cost effectiveness of different hemoglobin targets in hemodialysis patients treated with erythropoietin. *Kidney Int.* 2003 ;64:295-304.
81. Sugarman JR, Frederick PR, Frankenfield DL, Owen WF, McClellan WM. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative clinical practice guidelines: process, outcomes, and implications. *Am J Kidney Dis.* 2003;42:806-12.
82. Thomas D, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G for the Hemodialysis (HEMO) Study Group. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. *Kidney Int* In press.
83. Szczech LA, Reddan DN, Klassen PS, Coladonato J, Chua B, Lew NL, Lowrie EG, Lazarus JM, Owen WF. Interactions between dialysis-related volume exposures, nutritional surrogates, and mortality among ESRD patients. *Nephrol Dial Transplant.* 2003;18:1585-91.
84. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, Owen WF. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. *J Am Soc Nephrol.* 2003;14:2373-80.
85. Hou FF, Hao R, Owen WF, Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. *Am Soc Nephrol.* 2004;15:1889-96.
86. Manns B, Stevens L, Miskulin D, Owen WF, Winkelmayr WC, Tonelli Marcello A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. *Kidney Int.* 2004;66:1239-47.
87. Thomas D, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G for the Hemodialysis (HEMO) Study Group. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. *Kidney Int.* 2004;65:1386-94.
88. Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G; Hemodialysis Study Group. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". *J Am Soc Nephrol.* 2005;16:3371-80.

89. Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. *J Am Soc Nephrol.* 2005;16:2162-9.
90. Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, Mendoza O, Goud N, Denjoy N, Costigan A, Verger C., Owen WF. Aseptic peritonitis secondary to peptidoglycan contamination of pharmacopeia standard dialysis solution. *Lancet.* 2005;365:588-94.
91. Szczech LA, Klassen PS, Chua B, Hedayati SS, Flanigan M, McClellan WM, Reddan DN, Rettig RA, Frankenfield DL. Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. *Kidney Int* 2006;69:2094-100.
92. Manns B, Owen WF Jr, Winkelmayr WC, Devereaux PJ, Tonelli M. Surrogate markers in clinical studies: problems solved or created? *Am J Kidney Dis.* 2006;48:159-66.
93. Winkelmayr WC, Mehta J, Chandraker A, Owen WF, Avorn J: Predialysis nephrologist care and access to kidney transplantation in the United States. *Am J Transplant* 2007;7:872-9.
94. Dolor RJ, Yancy WS Jr, Owen WF, Matchar DB, Samsa GP, Pollak KI, Lin PH, Ard JD, Prempeh M, McGuire HL, Batch BC, Fan W, Svetkey LP: Hypertension Improvement Project (HIP): study protocol and implementation challenges. *Trials.* 2009;26:10-13.

### **Chapters in Books**

1. Austen KF, Owen WF: Regulation of eosinophil programmed cell death and the subsequent priming of ligand mediated functions by the eosinophil-directed hematopoietins, Ch 50. In S Nigam, KV Honn, LJ Marnett, and TL Walden, Jr., eds. *Eicosanoids and other bioactive lipids in cancer, Inflammation and Radiation Injury: Proc Second International Conference*, Berlin. Norwell: Kluwer Academic Publishers, 1992:255-9.
2. Owen WF: Surrogates of nutritional status as prognostic indicators for elderly hemodialysis patients. In: DG Oreopoulos, MF Michelis, and S Herschorn, eds. *Nephrology and urology in the aged patient*. Dordrecht: Kluwer Academic Publishers, 1993:303-7.
3. Owen WF: Interleukin-5 activity in tryptophan-associated eosinophila-myalgia syndrome. In W Kochen, ed. *Current prospects of L-tryptophan in medicine: consequences*. Berlin: W. de Gruyter, 1993:248-250.
4. Owen WF, Lazarus JM: Dialytic management of acute renal failure. In: B Brenner and JM Lazarus, eds. *Acute renal failure*. New York: Churchill Livingstone, 1993:487-525.
5. Owen WF: Eosinophil heterogeneity. In H Smith and RM Cook, eds. *The handbook of immunopharmacology*. London: Academic Press, 1993:57-72.
6. Owen WF: Interactions between eicosanoids and regulatory cytokines. In: C Robinson, ed. *Lipid mediators in allergic diseases of the respiratory tract*. London: CRC Press, 1994:191-206.
7. Owen WF, Austen KF: Cytokine regulation of eosinophil-mediated inflammatory reactions by modulation of programmed cell death and subsequent priming for augmented function. In: GJ Gleich and AB Kay, eds. *Eosinophils: immunological and clinical aspects*. New York: Marcel Dekker, 1994:239-54.
8. Owen WF, Denker BM, Lazarus JM: Medical aspects of hemodialysis. In: B Brenner and FC Rector, eds. *The Kidney*. Philadelphia: W. B. Saunders, 1995:2223-98.
9. Chertow GM, Owen WF, Lazarus JM: Conventional hemodialysis for acute renal failure. In: R Bellomo, and C Ronco, eds. *Acute renal failure in the critically ill*, Berlin: Springer-Verlag, 1995:265-97.
10. Owen WF: Dialysis in the intensive care setting. In: JM Rippe, RS Irwin, MP Fink, and FB Cerra, eds. *Intensive care medicine*. Boston: Little, Brown and Co., 1996:1057-81.
11. Boyce J, Owen WF: Interleukin 3, granulocyte-macrophage colony-stimulating factor,

- interleukin 5 and their receptors. In: R Townley, ed. Immunopharmacology of Allergic Disease, London: Marcel Dekker, 1996:394-403.
12. Boyce J, Owen WF: Idiopathic hypereosinophilic syndrome. In: A. Kaplan, ed. Allergy, New York: Churchill and Livingstone, 1997:861-75.
  13. Owen WF: Nutritional status and survival in ESRD patients. In: S Massry, ed. Mineral and Electrolyte Metabolism, Basel: Krager AG, 1998:24:72-81.
  14. Lau T, Owen WF: Adequacy of hemodialysis. In: H Brady, eds. Renal therapeutics: a companion to the kidney. Philadelphia: W. B. Saunders, 2000:57-79.
  15. Lau T, Owen WF: Adequacy of hemodialysis. In: Owen WF, Perreira B, Sayegh M, eds. Dialysis and transplantation: a companion to the kidney. Philadelphia: W. B. Saunders, 2000:57-79.
  16. Lacson E, Owen WF. Dialysis Management in the Cardio-thoracic ICU (Chapter 16). In: London G and Loscalzo J (eds). Cardiovascular Disease in End-Stage Renal Failure 1st ed., Oxford University Press, 2000
  17. Lacson E, Owen WF. Individualized Hemodialysis Treatment Regimens (Chapter 84, Section 1E). In: Massry SG and Glassock RJ (eds). Textbook of Nephrology, 4th ed., Lippincott Williams & Wilkins Publishers, 2000
  18. Denker BM, Chertow G, Owen WF: Medical aspects of hemodialysis. In: B Brenner and FC Rector, eds. The Kidney. Philadelphia: W. B. Saunders, 2000.
  19. Reddan D, Szczech L, Owen WF. Acute renal failure. In: Rakel RE and Bope ET, eds. Conn's Current Therapy. Philadelphia: W.B. Saunders, 2001:736-42.
  20. Reddan D, Szczech LA, Conlon P, Owen WF. Contextual issues in comparing outcomes and care processes for ESRD patients around the world. In: Levin NW and Ronco C, eds. Advances in End-Stage Renal Disease 2001;19:152-6.
  21. Lau T, Chertow G, Owen WF: Dialysis in the intensive care setting. In: JM Rippe, RS Irwin, MP Fink, and FB Cerra, eds. Intensive Care Medicine. Boston: Little, Brown and Co., 2003.
  22. Lau T, Acchiardo S, Owen WF: Dialysis in the intensive care setting. In: JM Rippe, RS Irwin, MP Fink, and FB Cerra, eds. Intensive Care Medicine. Boston: Little, Brown and Co., 2006.
  23. Owen WF, Miller L. Communications. In: S Wartman, ed. Enhancing the Professional Culture and Accountability of Academic Health Sciences Center in a Policy Context. Radcliff Publishing. In press.

### **Textbooks**

1. Owen WF, Perreira B, Sayegh M, eds. Dialysis and transplantation: A companion to the kidney. Philadelphia: W. B. Saunders, 2000.
2. Owen WF, Perreira B, Sayegh M, eds. Dialysis and transplantation: A companion to the kidney. (Italian edition) Philadelphia: W. B. Saunders, 2002.

### **Scientific Reviews**

1. Hemodialysis Adequacy Work Group: NKF-DOQI clinical practice guidelines for hemodialysis. In: Dialysis Outcomes Quality Initiative, Philadelphia, National Kidney Foundation, 1997.
2. Hemodialysis Adequacy Work Group: NKF-KDOQI clinical practice guidelines for hemodialysis: an update. In: Kidney Dialysis Outcomes Quality Initiative, Philadelphia, National Kidney Foundation, 2000.
3. Renal Physicians Association and American Society of Nephrology Shared Decision Making in the Appropriate Initiation and Withdrawal from Dialysis. Clinical Practice Guideline Number 2. Rockville, MD, RPA 2000
4. Renal Physicians Association's Appropriate Preparation of the Patient for Renal Replacement Therapy. Clinical Practice Guideline Number 3. Rockville, MD, RPA 2002.

5. McCrory D, Klassen P, Rutschmann O, Coladonato J, Yancy W, Reddan D, Gray R, Owen W, Shurr E, and Matchar D: Evidence Report: Appropriate Patient Preparation for Renal Replacement Therapy. October 2002. Rockville, MD, Renal Physicians Association.

### **Editorials**

1. Owen WF, Norris K: Nephrologists should be the primary care physician for minority, poor dialysis patients. *Nephrol News & Issues* 1994;8:54-5, 58.
2. Owen WF: Why the nephrologist should be the primary care physician for dialysis patients. *Dialysis Times*. 1994;1:1-2.
3. Owen WF: Defining a minimal frequency for nephrologist and patient interactions in the out-patient hemodialysis unit. *Dialysis Times* 1994;1:4-5.
4. Chertow G, Owen WF, Lazarus JM: Outcomes of older patients receiving chronic dialysis [letter]. *J Am Med Assoc* 1994;272-4.
5. Owen WF: An alternative view of the consequences of an extension of the Medicare Secondary Payer Period. *Nephrol News & Issues* 1995;9:14-5.
6. Norris KC, Owen WF: The dilemma of hypertension in the ESRD African-American community. *Nephrol News & Issues* 1995;9:14-6, 24-5, 38.
7. Owen WF: Are there too many dialysis units? *Dialysis Times* 1995;2:1-2.
8. Owen WF: Introduction: a lesson in history and medicine. *Adv Renal Replacement Ther* 1997;4:1-2.
9. Owen WF: A critique of the General Accounting Office's study of dialysis laboratory testing. *Nephrol News & Issues*. In press.
10. Owen WF, Nissenson A: Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation [letter]. *N Engl J Med* 2000;342:1054-5.
11. Szczech LA, Reddan DN, Lowrie EG, Owen WF: Dose of hemodialysis and survival: can we trust important outcomes to a flawed measure? *Int J Artif Organs* 2000;23:411-4.
12. Charytan C, Kaplan AA, Paganini E, Weiss J, Owen WF. The role of the nephrologist in the intensive care unit. *Am J Kidney Dis* 2001;38:426-9.
13. Reddan D, Owen WF. IgA nephropathy and inhibitors of the renin-angiotensin system: is reduction in proteinuria adequate proof of efficacy? *Am J Kidney Dis* 2001;38:182-5.
14. Lacson E, Teng M, Lazarus JM, Lew N, Lowrie E, Owen WF. Calculation and public use of the unit-specific standardized mortality ratio. *Am J Kidney Dis* 2001;38:214-7.
15. Coladonato JA, Szczech LA, Owen WF. Strategies to enhance the detection and treatment of unrecognized chronic kidney disease. *J Clin Outcomes Manage* 2001;8:34-40.
16. Wolfe RA, Held PJ, Port FK, Lacson E, Teng M, Lazarus JM, Lew N, Lowrie EG, Owen WF. Calculation and public use of the unit-specific standardized mortality ratio. *Am J Kidney Dis* 2001;38:214-a-217-a.
17. Coladonato JA, Szczech L, Friedman EA, Owen WF. Does calcium kill ESRD patients -- the skeptic's perspective. *Nephrol Dialysis Transplant* 2002; 17:229-32.
18. Henderson L, Owen WF. *Int. J. Art. Org.* 25:496-498:2002
19. Coladonato J, Klassen P, Owen WF. Perception versus reality of the burden of chronic kidney disease in the United States. *J Am Soc Nephrol*. 2002;13:1686-8.
20. Griffith TF, Coladonato JA, Owen WF. Does time of day of hemodialysis affect survival? *JAMA*. 2002 13;287:1262-3
21. Griffith TF, Reddan DN, Klassen PS, Owen WF. Left ventricular hypertrophy – a surrogate end point or correlate of cardiovascular events in kidney disease? *Nephrol Dialysis Transplant* 2003;18:1-4.

22. Tonelli M, Owen WF, Jindal K, Winkelmayr WC, Manns B. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. *Kidney Int.* 2004 Oct;66(4):1712; author reply 1712-3
23. Owen WF. Inequality in quality: are patient health activation and CQI corrective approaches? *J Am Soc Nephrol.* 2004;15:2951-2
24. Owen WF, Carmona R, Pomeroy C. Failing another national stress test on health disparities. *JAMA.* 2020 19;323:1905-6

### **Non-Refereed Invited Publications**

1. Rothenberg ME, Owen WF, Stevens RL: Mast cells and eosinophils. In: MH Friedlaender, ed. *Int Ophthal Clinics.* Little, Brown and Co. 1988;28:267-74.
2. Silberstein DS, Austen KF, Owen WF: Hematopoietins for eosinophils: Glycoprotein hormones that regulate the development of inflammation in eosinophil-associated disease. In: DW Golde, ed. *Hematol/Oncol Clinics No Amer. Hematopoietic Growth Factors.* Philadelphia: WB Saunders Co. 1989;3:511-23.
3. Owen WF: Precipitation of aluminum encephalopathy in a patient receiving deferoxamine. *Sem Dialysis.* 1989;2:56-9.
4. Owen WF: Erosive spondylarthropathy in a long-term chronic hemodialysis patient. *Sem Dialysis.* 1989;2:85-8.
5. Rothenberg ME, Owen WF, Austen KF: Cellular interactions regulate the postmitotic differentiation of human eosinophils. In: AJ Lewis, N Doherty, N Ackerman, eds. *Therapeutic approaches to inflammatory diseases.* 1989;1-13.
6. Owen WF: A new look at eosinophils in inflammatory disorders. *Innovations Rheum.* 1989;2:16.
7. Sheff DM, Owen WF, Austen KF. Eosinophil phenotypes and LTC<sub>4</sub> generation in vitro and in hypereosinophilic states. *Adv Prostaglandins Thromboxane Leukotrienes.* 1990;21:481-84.
8. Gravallesse EM, Baker N, Lester S, Kay J, Owen WF: Musculoskeletal manifestations in  $\beta$ 2-microglobulin amyloidosis. *Arthritis Rheum.* 1992;35:592-602.
9. Ginsberg E, Owen WF: Endocrine function in women with end stage renal disease. *Sem Dialysis,* 1994;7:149-50.
10. HEMO Study Group: The Hemodialysis Study: rationale for selection of interventions. *Sem Dialysis* 1996;9:24-33.
11. Owen WF: Is the NIH HEMO Study well-designed? *Sem Dialysis* 1996;9:21-3.
12. Owen WF: What are major changes in dialysis recommended by DOQI? *Sem Dialysis* 1997.
13. Hemodialysis Adequacy Work Group: NKF-DOQI clinical practice guidelines for hemodialysis. *Abst Clin Care Guidelines* 1998;10:1-4.
14. Owen WF: NKF-DOQI clinical practice guidelines for hemodialysis adequacy. *Abst Clin Care Guidelines* 1998;10:5.
15. Owen WF: Status of hemodialysis adequacy in the United States; Does it account for improved patient survival. *Am J Kidney Dis* 1998; 32 (suppl 4) S39-43.
16. Owen WF, Charytan C: Workshop on nutritional support in dialysis with a focus on the role of intradialytic parenteral nutritional. Introduction. *Am J Kidney Dis* 1999;33:1-2.
17. Owen WF, Szczech L, Johnson C, Frankenfield D. National perspective on iron as a clinical performance measure of maintenance hemodialysis patients. *Am J Kidney Dis* 1999;34:S1-9.
18. Owen WF. Introduction. *Am J Kidney Dis* 1999;34:S1-2.
19. Lacson E, Owen WF. Cardiac disease in dialysis patients: interactions between hemodialysis adequacy and nutrition. *Sem Dialysis* 1999;12:112-6.
20. Reddan D, Owen WF. I am a hemodialysis patient and my hematocrit fluctuates, why is this?



Renalife 2000; 15:18-9.

21. Lacson E, Owen WF, Lowrie EG. Linking inflammation, malnutrition, and mortal risk. *Sem Dialysis* 2000;13:163-75.
22. Reddan D, Klassen P, Szczech LA, Owen WF. Racial disparity in the ESRD Program. *Sem Dialysis* 2000;13:399-403.
23. Hou FF, Reddan DN, Wong KS, and Owen WF. Pathogenesis of  $\beta$ 2-microglobulin amyloidosis: role of monocytes/macrophages. *Sem Dialysis* 2001;14:1-5.
24. Eknoyan G, Levin N, Eschbach J, Golper T, Owen WF, Schwab S, Steinberg E. Continuous quality improvement: DOQI becomes K/DOQI and is updated. *Am J Kidney Dis.* 2001;37:179-94,.
25. Owen WF, Coladonato J, Szczech L, Reddan D. Explaining counter-intuitive clinical outcomes predicted by Kt/V. *Sem Dial.* 2001;14:268-70.
26. Chua B, Owen WF, Jr., Reddan DN. Peripheral vascular disease and ESRD: what is the most appropriate intervention? *Int J Artif Organs.* 2002;25:3-7.
27. Szczech LA, Coladonato JA, Owen WF. Concepts in the interpretation of the medical literature: Part I. An introduction to epidemiology and biostatistics and issues in interpretation of studies. *Sem Dialysis* 2002;15(1):60-5.
28. Ramirez SPB, Hsu SIH, Nandakumar M, Friedman E, Durai TT, Owen WF. Funding ESRD care through charity: the paradigm of the National Kidney Foundation of Singapore. *Sem Nephrol* In press.
29. Owen WF, Szczech L, Frankenfield DL. Health care system interventions for inequality in quality: corrective action through evidence-based medicine. *J Nat Med Assoc* 2002;94:83S-91S.
30. Owen WF, Young VR, Ajami A, Castillo L. Journal Club -- Authors reply for Arginine, citrulline, and nitric oxide metabolism in end stage renal disease patients. *Am J Kidney Dis.* In press.
31. Szczech LA, Coladonato JA, Owen WF. Concepts in the interpretation of the medical literature: Part II. Concepts in the interpretation of the medical literature: Study designs and their potential influence on conclusions. *Semin Dial.* 2002;15:207-11.
32. Fan Fan Hou and Owen WF.  $\beta$ 2 microglobulin amyloidosis: role of monocyte/ macrophage. *Current Opinion in Nephrology and Hypertension* In press.
33. Szczech LA, Coladonato JA, Owen WF. Concepts in the interpretation of the medical literature: "a difference?" *Semin Dial.* 2002;15:347-51.
34. McCullough PA, Bakris GL, Owen WF, Klassen PS, Califf RM. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. *Am Heart J.* 2004 Aug;148(2):243-51.
35. Bolton WK, Owen WF. Preparing the patient for renal replacement therapy. Teamwork optimizes outcomes. *Postgrad Med.* 2002 Jun;111(6):97-8, 101-4, 107-8.
36. Owen WF. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. *J Am Soc Nephrol.* 2003;14 (7 Suppl 2):S76-80.
37. Hedayati S., Owen WF. Behandlungsmodalitäten für Patienten mit chronischer Nierenerkrankung in den USA: ein dringender Ruf nach Verbesserung. *Klinische Nephrologie* 2002.
38. Owen WF Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement.
39. Owen WF Jr. Inequality in quality: are patient health activation and CQI corrective approaches? *J Am Soc Nephrol.* 2004;15:2951-2
40. Orlando LA, Owen WF, Matchar DB. Relationship between nephrologist care and progression of chronic kidney disease. *NC Med J.* 2007;68(1):9-16.

41. Abrams JS, Owen WF Jr, Brenner JC, Donlen J, Leone P, Carson JL, Slater EE. Perspectives on humanism in medicine from the 2012 Edward J. III Excellence in Medicine honorees. 2012 Spring, 5(2):4-9.

### **National Clinical Practice Guidelines and Performance Measures**

Each of the Guidelines was chosen for inclusion in the national registry of approved guidelines by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.

1. Hemodialysis Adequacy Clinical Practice Guideline Dialysis Outcomes Quality Initiative, Chairman, Sponsored by the National Kidney Foundation, 1995-1997, revised 2001
2. Appropriate Patient Preparation for Renal Replacement Therapy, Sponsored by the Renal Physicians Association, 2000-02
3. Selection Criteria for Initiating and Withdrawing Renal Replacement Therapy, Vice-Chairman, Sponsored by the Renal Physicians Association and American Society of Nephrology, 1996-98

### **ROLES WITH PROFESSIONAL JOURNALS**

#### **Editorial Boards**

- Journal of the American Society Nephrology, Associate Editor, 2001-2002
- Up-To-Date, Co-editor, 2000-03
- International Journal of Artificial Organs, 2000-02
- Nephrology News and Issues, 1998-07
- Advances in Renal Replacement Therapy, 1998-2002
- American Journal of Kidney Disease, 1996-2000
- Perspectives in Hypertension and Renal Disease, 1989-90
- Seminars in Dialysis, Founding Associate Editor, 1988-95

#### **Journal Reviewer**

Health Services Research Journal, Journal of the American Medical Association, New England Journal of Medicine, Journal of the National Medical Association, Journal of Immunology, Journal of Clinical Investigation, Journal of Biochemistry, Journal of the American Society Nephrology

#### **ADDITIONAL PERSONAL INFORMATION**

- Birthplace: Memphis, Tennessee, USA
- Marital Status: Married (spouse – Alice C. Owen), Adult Children (Lauren & William III)
- Hobbies: Analog & valve music reproduction, reading, movies

*Updated October 2020*

**Appendix I.**

Program/Course Title	Role	Participants			
		Students	Residents/Fellows	Faculty	Community
<b>Harvard/Brigham &amp; Women's Hosp (1994-99)</b>					
Introduction to Clinical Medicine	Instructor	x			
Morbidity and Mortality Conference	Instructor	x	x	x	
Professor's Rounds	Instructor	x	x		
Primary Care Subspecialty Conference	Instructor	x	x	x	
Kidney Disease Didactic for Fellows	Director	x	x		
Intensive Review of Dialysis	Co-Director	x	x	x	x
Dialysis Controversies	Co-Director	x	x	x	x
<b>National Kidney Foundation Singapore (1997-2004)</b>					
Global Update of Nephology	Director		x	x	x
<b>Duke (1999-2001)</b>					
Millie & Earl Dalbey Renal Research Fellowship	Director		x		
Renal Health Policy and Economics Fellowship	Director		x		
Medical Renal Business Certification	Co-Director			x	x
<b>American University Caribbean (2016)</b>					
Social Determinants of Health	Instructor	x		x	

## PROFESSIONAL REFERENCES\*

1. DR. IVOR BENJAMIN, MD  
Immediate Past President of the American Heart Association; Director of the Cardiovascular Center, Medical College of Wisconsin  
8701 W. Watertown Plank Rd, Milwaukee, WI 53226  
Business (520) 749-9655 ext. 4889, mobile (520) 258-8007, Email: [rcarmona@canyonranch.com](mailto:rcarmona@canyonranch.com)  
Dr. Benjamin was a Robert Wood Johnson Foundation Fellow and academic colleague.
2. DR. RICHARD H. CARMONA, MD, MPH  
17<sup>th</sup> Surgeon General of the United States; Board of Trustees of Ross University School of Medicine, Chief of Health Innovation at Canyon Ranch  
8600 E. Rockcliff Rd, Tucson, AZ 85750-9733  
Business (520) 749-9655 ext. 4889, mobile (520) 258-8007, Email: [rcarmona@canyonranch.com](mailto:rcarmona@canyonranch.com)  
Dr. Carmona is a member of the Academic Affairs Committee of RUSM Board of Trustees.
3. MR. AUTRY O. V. PETE DEBUSK  
Chairman and Founder of DeRoyal Industries; Chairman of the Board of Trustees of Lincoln Memorial University (LMU); Co-founder of LMU Debusk School of Osteopathic Medicine; and former member of the MedPAC Commission. Holder of the US' first medical device patent.  
DeRoyal Inc., 200 Debusk Lane, Powell, TN 37849  
Business (865) 362-1322, Mobile (865) 216-6830, Email:  
Mr. DeBusk hosted RUSM at LMU after the dislocation from Dominica.
4. DR. VICTOR J. DZAU, MD  
President of National Academy of Medicine of US National Academy of Sciences; Past President and CEO of Duke University Health System; Past Board Chair the Association of Academic Health Centers  
500 5<sup>th</sup> Street NW, Washington, DC 20001  
Business (202) 334-3300, Mobile (617) 470-3591, Email: [vdzau@nas.edu](mailto:vdzau@nas.edu)  
Dr. Dzau was an advisor to HH Sheikh Moza Bindt Nasser and Board Chair of the Association of Academic Medical Centers.
5. DR. VIVIAN W. PINN, MD  
Founding Director of the Office of Research on Women's Health, US National Institutes of Health; Past President of National Medical Association; Senior Scientist Emerita at NIH's Fogarty International Center; Chair of Department of Pathology at Howard University  
2740 Unicorn Lane, NW, Washington, DC 20015

Home (202) 966-5628, Mobile (202) 441-5170, Email: [vwypinn@gmail.com](mailto:vwypinn@gmail.com)  
Dr. Pinn is a career mentor and my medical school Dean.

6. DR. CLAIRE POMEROY, MD, MBA  
CEO & President, Albert & Mary Lasker Foundation  
405 Lexington Ave., 32<sup>nd</sup> floor Suite A  
New York, NY 10174  
Business (212) 286-0222, Mobile (646) 255-5049, Email: [cpomeroy@laskerfoundation.org](mailto:cpomeroy@laskerfoundation.org)  
Dr. Pomeroy is Past Board Chair for the Association of Academic Health Centers
  
7. DR. GRIFFIN RODGERS, MD, MBA  
Director, National Institute of Diabetes, Digestive, and Kidney Diseases  
31 Center Drive, Room 9A52  
Bethesda, MD 20892  
Business (301) 496-5741, Mobile (301) 768-7796, Email: [griffin.rodgers@nih.gov](mailto:griffin.rodgers@nih.gov)  
Dr. Rodgers is a longstanding professional colleague, who is familiar with my administrative leadership.
  
8. DR. HAROLD SHAPIRO, PHD  
Past President Princeton University; Past President University of Michigan University; Past Chairman of Board of Directors of DeVry Education Group (now Adtalem Global Education), and Board Member of Hospital Corporation of America  
359 Wallace Hall, Princeton University, Princeton NJ 08544  
Business (609) 258-6184, Email: [hts@princeton.edu](mailto:hts@princeton.edu)  
Dr. Shapiro chaired the Search Committee that selected me as 3<sup>rd</sup> President of UMDNJ. He also chaired the Academic Affairs Committee of UMDNJ's Board of Trustees.
  
9. DR. MICHAEL WHITCOMB, MD  
Former Senior Vice President and Director of Medical Education, Association of American Medical Schools  
Business (609) 258-6184, Mobile (410) 271-2330, Email:  
Consultant for medical school acquisition and LCME accreditation

\* Please alert me before contacting References.